v3.26.1
Note 10 - Segment Information - Summary of Segment Loss (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue $ 0 $ (27)
Employee expense (not including stock-based compensation) 1,635 1,338
Development and clinical trial expense 919 458
Other general and administrative expense(a) [1] 1,076 927
Other segment income, net(b) [2] (1,074) (30)
Discontinued operations 0 (73)
Segment and condensed consolidated net loss $ (2,556) $ (2,593)
[1] Other general and administrative expense includes consulting and professional services fees, insurance, facilities and other corporate expenses.
[2] Other segment income, net includes fair value adjustments to warrant liability, interest income, and stock-based compensation expense and marketing support.